Can you take Clofarabine with Vivimusta?

Clofarabine has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Clofarabine causes myelosuppression which may be severe and prolonged. Serious and fatal hemorrhage, including cerebral, gastrointestinal and pulmonary hemorrhage associated with thrombocytopenia has occurred. It is recommended to monitor complete blood counts including platelets and coagulation parameters and treat accordingly. Care should be exercised when using this agent in patients with bone marrow depression.

The bendamustine in Vivimusta has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Adult and pediatric patients treated with bendamustine have experienced Infection, including pneumonia, sepsis, septic shock, and death. Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections. Therapy with bendamustine should be administered cautiously in patients with compromised bone marrow reserve. Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently.

The bendamustine in Vivimusta has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine. Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections. Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection. Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.

Clofarabine has a major potential interaction with Infection.

Clofarabine injection may cause acute renal failure. Patients with infection, sepsis, or tumor lysis syndrome may be at increased risk of renal toxicity when treated with clofarabine injection. It is recommended to monitor patients for renal toxicity and interrupt or discontinue clofarabine injection as necessary.

The bendamustine in Vivimusta has a moderate potential interaction with Infection.

Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine. Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections. Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection. Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.

The bendamustine in Vivimusta has a major potential interaction with Liver Disease.

Bendamustine injection should be used with caution in patients with hepatic impairment. Bendamustine injection should not be used in patients with moderate (AST or ALT 2.5 to 10 X ULN and total bilirubin 1.5 to 3 X ULN) or severe (total bilirubin greater than 3 X ULN) hepatic impairment.

Clofarabine has a moderate potential interaction with Liver Disease.

Severe and fatal hepatotoxicity, including hepatitis and hepatic failure, has occurred with the use of clofarabine. Monitor hepatic function and for signs and symptoms of hepatitis and hepatic failure. It is recommended to discontinue clofarabine immediately for Grade 3 or greater liver enzyme and/or bilirubin elevation of the liver, or veno-occlusive disease is suspected. Care should be exercised when using this agent in patients with liver disease.

Clofarabine has a moderate potential interaction with Noninfectious Colitis.

Fatal and serious cases of enterocolitis, including neutropenic colitis, cecitis, and C. difficile colitis, have occurred during treatment with clofarabine. This has occurred more frequently within 30 days of treatment, and in the setting of combination chemotherapy. Enterocolitis may lead to necrosis, perforation, hemorrhage or sepsis complications. Monitor patients for signs and symptoms of enterocolitis and treat promptly. Care should be exercised when treating patients presenting with symptoms of enterocolitis.

The bendamustine in Vivimusta has a major potential interaction with Renal Dysfunction.

Bendamustine injection should be used with caution in patients with mild or moderate renal impairment. Bendamustine injection should not be used in patients with CrCL < 40 mL/min.

Clofarabine has a moderate potential interaction with Renal Dysfunction.

The use of clofarabine may cause acute renal failure. It is recommended to reduce the dose by 50% in patients with CrCl of 30 to 60 mL/min. At this time the manufacturer is not able to make a dosage recommendation in patients with CrCl less than 30 mL/min or in those on dialysis as there is insufficient information in this patient population. Care should be exercised when using this agent in patients with renal dysfunction.

Clofarabine has a major potential interaction with Sepsis.

Clofarabine injection may cause acute renal failure. Patients with infection, sepsis, or tumor lysis syndrome may be at increased risk of renal toxicity when treated with clofarabine injection. It is recommended to monitor patients for renal toxicity and interrupt or discontinue clofarabine injection as necessary.

Clofarabine has a major potential interaction with Tumor Lysis Syndrome.

Clofarabine injection may cause acute renal failure. Patients with infection, sepsis, or tumor lysis syndrome may be at increased risk of renal toxicity when treated with clofarabine injection. It is recommended to monitor patients for renal toxicity and interrupt or discontinue clofarabine injection as necessary.